First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors

Inclusion Criteria: * Histologically or cytologically confirmed advanced malignant solid tumor that is refractory to, intolerant of, or for which no standard of therapy is available * Measurable or evaluable disease * ECOG Performance Status of ≤2 * No known active central nervous system (CNS) tumors or CNS metastases * Adequate organ function Exclusion Criteria: * Myocardial infarction within the last 6 months of study Day 1, symptomatic congestive heart failure (New York Heart Association Classification \> Class II), unstable angina, or unstable cardiac arrhythmia requiring medication * History of surgery within 28 days prior to enrollment or anticipated surgery during the study period * Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy) within 28 days of study Day 1 (six weeks for nitrosoureas, mitomycin C, antibodies, or molecular agents with t½ \>10 days); (concurrent use of hormone therapy for breast or prostate cancer is permitted) * Treatment with immune modulators including, but not limited to, cyclosporine and tacrolimus within two weeks prior to enrollment * Concurrent or prior (within 30 days of study Day 1) anticoagulation therapy; (low-dose warfarin \[\<2 mg/day\] for prophylaxis against central venous catheter thrombosis is allowed) * Patient with tumor that is infiltrating or invading a major blood vessel